Completed Equality Screenings - Quarter 4 - January 2015 - March 2015
Date published:
In fulfilling the commitments within its Equality Scheme the Department equality screens policies to assess the impact and determine if a full Equality Impact Assessment (EQIA) is required.
Documents
- Firefighters (Transitional and Consequential Provisions) Regulations (Northern Ireland) 2015
- NICE Clinical Guideline CG37 - Postnatal care - Addendum
- NICE Clinical Guideline CG131 - Colorectal cancer: The diagnosis and management of colorectal cancer – Addendum (1.2.2 & 1.2.4 Addendum )
- NICE Clinical Guideline CG189 - Obesity: identification, assessment and management of overweight and obesity in children, young people and adults
- NICE Clinical Guideline CG190 - Intrapartum care: care of healthy women and their babies during childbirth - This guideline updates and replaces NICE guideline CG55
- NICE Clinical Guideline CG191 - Pneumonia: Diagnosis and management of community- and hospital-acquired pneumonia in adults
- NICE Clinical Guideline CG192 - Antenatal and postnatal mental health: clinical management and service guidance
- NICE (Clinical) Guidelines (NG1) - Gastro-oesophageal reflux disease (GORD): recognition, diagnosis and management in children and young people children and young people
- NICE Technology Appraisal TA - Simeprevir in combination with peginterferon alfa and ribavirin for treating genotype 1 or 4 chronic hepatitis C
- NICE Technology Appraisal TA - Sipuleucel-T for the first line treatment of metastatic hormone relapsed prostate cancer.
- NICE Technology Appraisal TA326 - Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (review of TA196)
- NICE Technology Appraisal TA327 - Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
- NICE Technology Appraisal TA329 - Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262)
- NICE Technology Appraisal TA333 - Axitinib for the treatment of advanced renal cell carcinoma after failure of prior systemic treatment